M G Oefelein1, M Brant, K Crotty. 1. Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio 45414, USA.
Abstract
OBJECTIVES: Idiopathic thromboembolism has been associated with occult neoplasia; however, very limited information exists regarding a man's risk of occult prostate cancer after an idiopathic thromboembolic event. METHODS: We performed a case-control study of 209 consecutive men diagnosed with prostate cancer over a 3-year period, with 350 men diagnosed with benign prostatic hyperplasia (BPH) serving as control subjects. RESULTS: Men with idiopathic thromboembolism had a fivefold increased risk of prostate cancer compared with the BPH control group (risk ratio = 5.0, P = 0.002). The prostate-specific antigen (PSA) progression-free survival was not adversely affected after an idiopathic thromboembolic event. CONCLUSIONS: Our data suggest that men with idiopathic thromboembolism are at an increased risk for being diagnosed with prostate cancer. In men with idiopathic thromboembolism, attempts to diagnose prostate cancer, including digital rectal examination and serum PSA, warrant consideration.
OBJECTIVES:Idiopathic thromboembolism has been associated with occult neoplasia; however, very limited information exists regarding a man's risk of occult prostate cancer after an idiopathic thromboembolic event. METHODS: We performed a case-control study of 209 consecutive men diagnosed with prostate cancer over a 3-year period, with 350 men diagnosed with benign prostatic hyperplasia (BPH) serving as control subjects. RESULTS:Men with idiopathic thromboembolism had a fivefold increased risk of prostate cancer compared with the BPH control group (risk ratio = 5.0, P = 0.002). The prostate-specific antigen (PSA) progression-free survival was not adversely affected after an idiopathic thromboembolic event. CONCLUSIONS: Our data suggest that men with idiopathic thromboembolism are at an increased risk for being diagnosed with prostate cancer. In men with idiopathic thromboembolism, attempts to diagnose prostate cancer, including digital rectal examination and serum PSA, warrant consideration.
Authors: Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg Journal: Lancet Oncol Date: 2010-04-13 Impact factor: 41.316